Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

As previously reported, BMO Capital downgraded Saia (SAIA) to Market Perform from Outperform with a price target of $285, down from $455. Saia ...